NEUROONE MEDICAL TECHNOLOGIES Corp 8-K

What Happened
NeuroOne Medical Technologies Corporation announced a 1-for-6 reverse stock split of its common stock. The Board approved the split on April 3, 2026, the company filed a Certificate of Amendment on April 14, 2026, and the reverse split will be effective at 5:00 p.m. Eastern Time on April 15, 2026. Trading on The Nasdaq Capital Market will begin on a split-adjusted basis at market open on April 16, 2026 under the existing symbol “NMTC.”

Key Details

• Reverse split ratio: 1-for-6 (every 6 pre-split shares become 1 post-split share).
• Effective timing: Certificate filed Apr 14, 2026; effective Apr 15, 2026 at 5:00 p.m. ET; Nasdaq trading split-adjusted Apr 16, 2026.
• Fractional shares: No fractional shares will be issued; holders entitled to fractions will receive a cash payment for the market value of the fractional share.
• Other adjustments: Proportional adjustments will be made to shares available under equity incentive plans and to outstanding options, warrants and convertible securities. New CUSIP for the post-split common stock: 64130M308.

Why It Matters
A reverse stock split reduces the number of outstanding shares and increases the per-share price proportionally; it does not change a stockholder’s relative ownership (except for cash-outs of fractional shares). For investors, expect adjusted share counts on holdings, option/warrant exercise terms to change proportionally, and a new CUSIP. The company notes forward-looking risks, including the potential impact on Nasdaq minimum bid price compliance, but the filing does not guarantee any particular market reaction or that listing compliance will be restored.